Evidence map›Paper›PMID 40404827›Full record

ArticleNature microbiology2025

Kaposi's sarcoma-associated herpesvirus induces mitochondrial fission to evade host immune responses and promote viral production.

Qing Zhu, Robert McElroy, Janvhi Suresh Machhar, Joel Cassel, Zihan Zheng, Behzad Mansoori, Hongrui Guo, Sen Guo, Christian Pangilinan, Jinghui Liang and 14 more

Abstract read
In one paragraph

Article in Nature microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Qing ZhuProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA.
Robert McElroyProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0009-0007-9791-3189
Janvhi Suresh MachharProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA.
Joel CasselProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA.
Zihan ZhengProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA.
Behzad MansooriProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA.
Hongrui GuoDepartment of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Sen GuoProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA.
Christian PangilinanProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-3913-7912
Jinghui LiangProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA.
Dongliang ShenProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA.
Lu ZhangProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA.
Qin LiuProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-9964-580X
Andrew V KossenkovProgram in Genome Regulation and Cell Signaling, The Wistar Institute, Philadelphia, PA, USA.
Dario C AltieriProgram in Genome Regulation and Cell Signaling, The Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-0617-3469
Paul M LiebermanProgram in Genome Regulation and Cell Signaling, The Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-3935-9921
Shou-Jiang GaoCancer Virology Program, University of Pittsburgh Medical Center Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-6194-1742
Pinghui FengSection of Infection and Immunity, Herman Ostrow School of Dentistry, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-8494-0205
Maureen E MurphyProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA.
Jikui SongDepartment of Biochemistry, University of California, Riverside, CA, USA.
Joseph M SalvinoProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-2184-5980
Qiming LiangCenter for Immune-Related Diseases at Shanghai Institute of Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jae U JungDepartment of Cancer Biology, Department of Infection Biology, and Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0003-4559-8774
Chengyu LiangProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA. cliang@wistar.org.ORCID http://orcid.org/0000-0001-6082-2143

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
TRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3M
Regulation of KSHV LatencyR01CA117830 · NCI · WISTAR INSTITUTE · PI PAUL M. LIEBERMAN · 2006 to 2026
$6.4M
Role of UVRAG-mediated Autophagy in Tumor SuppressionR01CA140964 · NCI · WISTAR INSTITUTE · PI LIANG, CHENGYU · 2009 to 2025
$5.4M
Mechanistic Insights into Mammalian DNA MethylationR35GM119721 · NIGMS · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI Jikui Song · 2016 to 2026
$5.3M
Transcriptional Reprogramming in Melanoma PlasticityR01CA289624 · NCI · WISTAR INSTITUTE · PI Chengyu Liang · 2024 to 2026
$3.0M
A cancer-derived truncating mutation in disease penetrance and progression of MSI CRCR01CA238457 · NCI · WISTAR INSTITUTE · PI LIANG, CHENGYU · 2020 to 2024
$2.9M
New control of oncogene activation in T-cell leukemiaR01CA262631 · NCI · WISTAR INSTITUTE · PI Chengyu Liang · 2022 to 2026
$2.6M
Structural analysis and therapeutic nanobody development of KSHV G-protein coupled receptorR01CA251275 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI JUNG, JAE U · 2020 to 2024
$2.5M
KSHV-mediated metabolic reprogramming for LANA expression and viral persistencyR01AI181758 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI Jae U Jung · 2024 to 2026
$2.0M
Targeting the host NDP kinase to abrogate viral disseminationR21DE028256 · NIDCR · WISTAR INSTITUTE · PI FENG, PINGHUI, LIANG, CHENGYU · 2019 to 2020
$447k
NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA117830NCI NIH HHS R01 CA140964NCI NIH HHS R01 CA238457NCI NIH HHS R01 CA251275NCI NIH HHS R01 CA262631NCI NIH HHS R01 CA289624NCI NIH HHS T32 CA009171NIAID NIH HHS R01 AI181758NIDCR NIH HHS R21 DE028256NIGMS NIH HHS R35 GM119721U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35GM119721
6 · The paper itself

Abstract

Mitochondrial dynamics are pivotal for host immune responses upon infection, yet how viruses manipulate these processes to impair host defence and enhance viral fitness remains unclear. Here we show that Kaposi's sarcoma-associated herpesvirus (KSHV), an oncogenic virus also known as human herpesvirus 8, encodes Bcl-2 (vBcl-2), which reprogrammes mitochondrial architecture. It binds with NM23-H2, a host nucleoside diphosphate (NDP) kinase, to stimulate GTP loading of the dynamin-related protein (DRP1) GTPase, which triggers mitochondrial fission, inhibits mitochondrial antiviral signalling protein (MAVS) aggregation and impairs interferon responses in cell lines. An NM23-H2-binding-defective vBcl-2 mutant fails to evoke fission, leading to defective virion assembly due to activated MAVS-IFN signalling. Notably, we identify two key interferon-stimulated genes restricting vBcl-2-dependent virion morphogenesis. Using a high-throughput drug screening, we discover an inhibitor targeting vBcl-2-NM23-H2 interaction that blocks virion production in vitro. Our study identifies a mechanism in which KSHV manipulates mitochondrial dynamics to allow for virus assembly and shows that targeting the virus-mitochondria interface represents a potential therapeutic strategy.

Indexed as

Herpesvirus 8, HumanHost-Pathogen InteractionsImmune EvasionMitochondrial DynamicsVirus ReplicationAdaptor Proteins, Signal TransducingCell LineDynaminsHEK293 CellsHumansInterferonsMitochondriaProto-Oncogene Proteins c-bcl-2Signal TransductionViral ProteinsVirus AssemblyAdaptor Proteins, Signal TransducingDNM1L protein, humanDynaminsInterferonsMAVS protein, humanProto-Oncogene Proteins c-bcl-2Viral Proteins

Identifiers

PMID40404827
PMCPMC12337130

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.